275 related articles for article (PubMed ID: 24798350)
61. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
62. A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate.
Matsuno H; Matsubara T
Mod Rheumatol; 2019 Nov; 29(6):919-927. PubMed ID: 30289287
[No Abstract] [Full Text] [Related]
63. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
64. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
Clin Exp Rheumatol; 2006; 24(5):529-33. PubMed ID: 17181921
[TBL] [Abstract][Full Text] [Related]
65. [IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy].
Fiocco U; Vezzù M; Cozzi L; Todesco S
Reumatismo; 2004; 56(1 Suppl 1):62-73. PubMed ID: 15201942
[TBL] [Abstract][Full Text] [Related]
66. A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis.
Wei W; Zhang LL; Xu JH; Xiao F; Bao CD; Ni LQ; Li XF; Wu YQ; Sun LY; Zhang RH; Sun BL; Xu SQ; Liu S; Zhang W; Shen J; Liu HX; Wang RC
Arthritis Res Ther; 2009; 11(6):R180. PubMed ID: 19951408
[TBL] [Abstract][Full Text] [Related]
67. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
Saleem B; Mackie S; Quinn M; Nizam S; Hensor E; Jarrett S; Conaghan PG; Emery P
Ann Rheum Dis; 2008 Aug; 67(8):1178-80. PubMed ID: 18234715
[TBL] [Abstract][Full Text] [Related]
68. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
[TBL] [Abstract][Full Text] [Related]
69. [Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis].
Botsios C; Sfriso P; Furlan A; Ostuni P; Biscaro M; Fiocco U; Todesco S; Punzi L
Reumatismo; 2007; 59(1):32-7. PubMed ID: 17435840
[TBL] [Abstract][Full Text] [Related]
70. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
[TBL] [Abstract][Full Text] [Related]
71. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial.
Ferraccioli GF; Assaloni R; Di Poi E; Gremese E; De Marchi G; Fabris M
Rheumatology (Oxford); 2002 Oct; 41(10):1109-12. PubMed ID: 12364628
[TBL] [Abstract][Full Text] [Related]
72. A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study.
Lila AM; Mazurov VI; Denisov LN; Nesmeyanova OB; Ilivanova EP; Eremeeva AV; Usacheva JV; Dokukina EA; Chernyaeva EV; Ivanov RA
Rheumatol Int; 2019 Sep; 39(9):1537-1546. PubMed ID: 31292709
[TBL] [Abstract][Full Text] [Related]
73. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).
Jung N; Hellmann M; Hoheisel R; Lehmann C; Haase I; Perniok A; Hallek M; Rubbert A
Clin Rheumatol; 2010 Oct; 29(10):1169-73. PubMed ID: 20532937
[TBL] [Abstract][Full Text] [Related]
74. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K;
Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669
[TBL] [Abstract][Full Text] [Related]
75. A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
Kameda H; Uechi E; Atsumi T; Abud-Mendoza C; Kamei K; Matsumoto T; Ponce de Leon D; Rehman MI; Zhang M; Radominski SC
Int J Rheum Dis; 2020 Jul; 23(7):876-881. PubMed ID: 32476277
[TBL] [Abstract][Full Text] [Related]
76. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment.
Kim J; Ryu H; Yoo DH; Park SH; Song GG; Park W; Cho CS; Song YW
J Korean Med Sci; 2013 Dec; 28(12):1716-22. PubMed ID: 24339699
[TBL] [Abstract][Full Text] [Related]
77. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis.
Temekonidis TI; Georgiadis AN; Alamanos Y; Bougias DV; Voulgari PV; Drosos AA
Ann Rheum Dis; 2002 Sep; 61(9):822-5. PubMed ID: 12176808
[TBL] [Abstract][Full Text] [Related]
78. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
[TBL] [Abstract][Full Text] [Related]
79. Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Genovese MC; Weinblatt ME; Mease PJ; Aelion JA; Peloso PM; Chen K; Li Y; Liu J; Othman AA; Khatri A; Mansikka HT; Leszczynski P
Rheumatology (Oxford); 2018 Nov; 57(11):1972-1981. PubMed ID: 30032191
[TBL] [Abstract][Full Text] [Related]
80. Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial.
Duan XW; Zhang XL; Mao SY; Shang JJ; Shi XD
Clin Rheumatol; 2015 Sep; 34(9):1513-9. PubMed ID: 26139202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
